Based on these findings, it is possible that therapeutic PD-1 blockade might work more effectively if the tumors have already been identified by the host immune system and PD-L1 expression in cancer and innate immune cells is the consequence of local IFN-γ production by tumor-activated T cells (151, 193). The gene discussed is IFNG; the disease is cancer.